文献速递免疫规划慢病防控与筛查

癌症患者接种COVID-19疫苗:第三剂后一年的免疫应答

COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
PubMed 文献 · Vaccine · 2024-03-17

本研究评估实体瘤患者接种第三剂抗SARS-CoV-2疫苗一年后的免疫应答,并分析癌症治疗对疫苗免疫原性的影响,同时纳入健康供者作为对照。结合抗体和中和抗体滴度分别采用化学发光免疫分析和蚀斑减少中和试验检测,T细胞应答采用多参数流式细胞术分析。结果显示接种三剂的癌症患者抗体滴度低于接种四剂者及健康供者,细胞免疫应答整体较低且以产TNFα的单功能T细胞为主;既往无SARS-CoV-2感染的癌症患者抗体滴度和T细胞应答均低于有既往感染者;免疫治疗与非免疫治疗患者体液应答无差异,但免疫治疗患者T细胞应答更强。

要点

  • 接种三剂的癌症患者抗体滴度低于接种四剂者及健康供者
  • 癌症患者整体细胞免疫应答较低,以产TNFα的单功能T细胞为主
  • 既往无SARS-CoV-2感染的癌症患者抗体滴度和T细胞应答均低于有既往感染者

核心结论

  • 癌症患者接种三剂疫苗后抗体滴度低于接种四剂者及健康供者,整体细胞免疫应答较低。
  • 既往无SARS-CoV-2感染的癌症患者抗体滴度和T细胞应答均低于有既往感染者。
  • 免疫治疗与非免疫治疗患者体液应答无差异,免疫治疗患者T细胞应答更强。
  • 作者认为结果强调癌症患者需要加强剂量以达到与健康供者相似的保护水平,并需考虑所接受的治疗以获得适当免疫应答。

研究设计与样本

  • 研究评估实体瘤患者接种第三剂抗SARS-CoV-2疫苗一年后的免疫应答,并评估癌症治疗对疫苗免疫原性的影响,纳入健康供者(HDs)作为对照。
  • 结合抗体和中和抗体滴度分别采用化学发光免疫分析(CLIA)和蚀斑减少中和试验(PRNT)检测,T细胞应答采用多参数流式细胞术分析。

主要发现

  • 接种三剂的癌症患者抗体滴度低于接种四剂的癌症患者及健康供者。
  • 癌症患者整体细胞免疫应答较低,以产TNFα的单功能T细胞为主。
  • 既往无SARS-CoV-2感染的癌症患者抗体滴度和T细胞应答均低于有既往感染者。
  • 免疫治疗与非免疫治疗患者体液应答无差异,免疫治疗患者T细胞应答更强。

临床怎么用

  • 作者认为结果强调癌症患者需要加强剂量以达到与健康供者相似的保护水平。
  • 作者认为需考虑癌症患者所接受的治疗以获得适当免疫应答。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer patients (CPs), being immunosuppressed due to the treatment received or to the disease itself, are more susceptible to infections and their potential complications, showing therefore an increased risk of developing severe COVID-19 compared to the general population. We evaluated the immune responses to anti-SARS-CoV-2 vaccination in patients with solid tumors one year after the administration of the third dose and the effect of cancer treatment on vaccine immunogenicity was assessed. Healthy donors (HDs) were enrolled. Binding and neutralizing antibody (Ab) titers were evaluated using chemiluminescence immunoassay (CLIA) and Plaque Reduction Neutralization Test (PRNT) respectively. T-cell response was analyzed using multiparametric flow cytometry. CPs who were administered three vaccine doses showed lower Ab titers than CPs with four doses and HDs. Overall, a lower cell-mediated response was found in CPs, with a predominance of monofunctional T-cells producing TNFα. Lower Ab titers and a weaker T-cell response were observed in CPs without prior SARS-CoV-2 infection when compared to those with a previous infection. While no differences in the humoral response were found comparing immunotherapy and non-immunotherapy patients, a stronger T-cell response in CPs treated with immunotherapy was observed. Our results emphasize the need of booster doses in cancer patients to achieve a level of protection similar to that observed in healthy donors and underlines the importance of considering the treatment received to reach a proper immune response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Campagna R, Dominelli F, Zingaropoli MA, et al. COVID-19 vaccination in cancer patients: Immune responses one year after the third dose. Vaccine. 2024. PMID: 38499458. doi:10.1016/j.vaccine.2024.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。